ESMO 2019 Congress | OncologyPRO

Abstract 2852

Background

Although definitive concurrent chemoradiotherapy (CRT) is considered standard of care for most of stage III NSCLC patients, neoadjuvant treatment followed by surgery can be considered for some potentially resectable patients. Rationales for neoadjuvant treatment are tumor regression effect before surgery, early eradication of micrometastasis and better tolerability of chemotherapy than in the post-surgical setting. Regarding potential benefits of combining PD-1 blockade with CRT, here we have an ongoing phase Ib trial which assesses the safety and feasibility of the combination of neoadjuvant CRT with durvalumab in potentially resectable stage III NSCLC (NCT03694236).

Trial design

Eligible patients with histologically confirmed NSCLC (potentially resectable clinical stage III according to the American Joint Committee on Cancer 8^th staging system) are enrolled. Patients receive CRT (weekly paclitaxel 45 mg/m² and carboplatin AUC 2 with radiotherapy of 45 Gy in 25 fractions) and durvalumab (Day 1 and 29, 1500mg) during 5 weeks followed by surgery. After surgery, patients are treated with durvalumab for one year (every 4weeks, 1500 mg). The primary endpoints are safety and tolerability. The secondary endpoints are objective response rate (ORR), R0 resection rate, disease-free survival (DFS), overall survival (OS), clinical or pathological downstaging rate and, pathologic complete response (pCR) rate in the primary tumor. Immune marker analysis by FACS, exome sequencing and RNA sequencing using cancer tissue of pre-treatment, after surgery, and after recurrence will be performed.Table:

1477TiP

Steps of trial	No. of patients	Considerations
Neoadjuvant (weekly paclitaxel 45 mg/m2 and carboplatin AUC 2, radiotherapy 45 Gy in 25 fractions, durvalumab day 1 and 29, 1500mg)	Stage 1¹	9	1) If patients of ≥ 5 has grade≥3 TRAE the trial holds 2) If patients of ≤ 4 has grade≥3 TRAE the trial proceeds to the 2nd stage.
Stage 2	21	If patients of ≤ 13(43%) has grade≥3 TRAE during the neoadjuvant treatment it will be considered tolerable and further analysis will be performed.²
Surgery	The time and modality of surgery will depend on the surgeon’s discretion. The maximum allowed interval between the end of neoadjuvant therapy and surgery is 9 weeks. If disease progresses during or after the neoadjuvant therapy, or if the surgeon thinks that the surgery is not feasible, concurrent chemoradiation or chemotherapy alone can be continued.
Adjuvant (durvalumab 1500mg for one year every 4 weeks, total of 13 times.)	The maximum allowed interval between the surgery and adjuvant therapy is 12 weeks.
Follow up	Response evaluation will be done until 5 years after the surgery.³ (Chest CT every 3 months, Abdominal pelvic CT at 1, 2, 5 years after the surgery)

Additional enrollment will be hold until the first 9 patients proceeds surgery.

Grade≥3 TRAE during neoadjuvant chemoradiotherapy is expected to be 30∼50% according to the previous data.

Assessed according to the Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1. TRAE; treatment-related adverse event, CT; Computed tomography.

Clinical trial identification

NCT03694236.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

AstraZeneca.

Disclosure

All authors have declared no conflicts of interest.

Poster Display session 1

2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)

Date

Session

Topics

Tumour Site

Presenters

Citation

Authors

Author affiliations

Resources

Abstract 2852

Background

Trial design

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Funding

Disclosure

Abstract 2852

Background

Trial design

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Funding

Disclosure

Resources from the same session